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across every stage, all of which are fully transparent, provides a unique combination 
of broadness, resilience and inclusiveness making it an ideal decision making tool.
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Objectives: Many aspects of QALY measurement in children are not yet fully 
developed. This study is aimed at contextualizing the mapping methodology 
in a field not yet covered: paediatric asthma. The objective is to derive utility 
values from non-preference-based questionnaires, the estimated utility values 
will be useful for QALY assessment by means of: i) evaluation of a linear map-
ping between the generic preference-based EQ-5D-3L (self- and proxy-versions) 
and the condition-specific non-preference-based Paediatric Asthma Quality of 
Life Questionnaire (PAQLQ) and Paediatric Asthma Caregiver’s Quality of Life 
Questionnaire (PACQLQ), respectively; ii) assessment of the capability of map-
ping to discriminate for disease severity. MethOds: Either PAQLQ or PACQLQ and 
EQ-5D-3L will be administrated to 170 asthma children (7-17 years of age) during 
a 24-month multicenter randomized placebo-controlled trial of allergen specific 
sublingual immunotherapy coded EudraCT No. 2012-005678-76/FARM94793N at 
baseline, month 12, and month 24 visits. Level of severity will be assessed using 
the Asthma Control Test (ACT) and the Childhood-ACT (C-ACT) questionnaires. 
The possibility of a linear mapping will be evaluated through a Tobit model, where 
either PAQLQ/PACQLQ will be tested as predictors of EQ-5D-3L answers. Capability 
of mapping to be sensible in changes of disease severity will be measured 
through a Pearson’s correlation between changes in estimated EQ-5D-3L scores 
and changes in ACT and C-ACT answers. Results: Linear mapping, if feasible, 
applies the statistical relationship between either PAQLQ or PACQLQ and EQ-5D-3L, 
being PAQLQ/PACQLQ answers predictors of EQ-5D-3L score. EQ-5D-3L and PAQLQ/
PACQLQ, as well as EQ-5D-3L built on PAQLQ/PACQLQ answers by applying the 
linear mapping is expected to discriminate for both patients’ level and changes 
in disease severity. cOnclusiOns: This study seeks to inform policy makers in 
their choice of the source of utility values and their discrimination across severity 
groups and responsiveness in asthma children.
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Objectives: Guidelines for economic evaluation from ISPOR and NICE recom-
mend the use of mean values rather than medians, but do not offer guidance for 
situations when mean values are not available. This study evaluated the impact 
of different methods of estimating means from medians, within the context of 
estimating treatment duration for drugs used to treat mCRC. MethOds: Clinical 
trials and prescribing information for drugs used to treat mCRC were reviewed 
for information on the mean, median, and range of treatment cycles. Various 
approaches were used to estimate mean values, including direct use of the median, 
a published equation considering the median and range, confidence intervals and 
interquartile range, and the use of distributions commonly used in survival analy-
sis. Where possible, the estimated means were compared with reported means 
from clinical trials. Results: Very few studies reported both median and mean 
treatment duration; direct use of the median under-predicted the mean by 23-39% 
and the published equation over-predicted the mean by 19-28%. Simple assump-
tions about the distribution of treatment durations performed best, predicting the 
reported mean within ±12%. The use of progression-free survival as a proxy for 
treatment duration over-predicted treatment duration by 5-38%, although esti-
mates were improved by accounting for early discontinuation. cOnclusiOns: 
By only considering the 50th percentile, the median may not provide an accurate 
representation of the outcomes in a population. It is important that researchers 
and budget-holders are aware of the limitations in the use of medians, and that 
they consider multiple estimation methods to estimate mean values for economic 
analyses.
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Objectives: Prostate cancer (PCa) incidence has been steadily increasing over the 
last twenty years, resulting in Ireland having the highest incidence rate in Europe 
in 2008. The main driver of this is wide-spread use of prostate specific antigen 
(PSA) testing in primary care as an ad-hoc detection mechanism. The objective of 
this research was to undertake a cost-effectiveness analysis of organised screening 
using PSA testing in Ireland. MethOds: Using a Bayesian Multi-Parameter Evidence 
Synthesis (MPES) framework, non-cost parameters were synthesised, informed by 
incidence, mortality and clinical data from the National Cancer Registry Ireland 
for men diagnosed with PCa in 2009. The MPES framework estimates unobserved 
parameters using available evidence and so facilitates analysis of interventions 
where observational data is limited. Average costs were estimated using project-
specific survey costs, Irish hospital costs (HSE Casemix) and costs published in the 
literature. Effectiveness of PSA testing was sourced from the literature. Utility scores 
were collected from 2,500 PCa survivors. The cost-effectiveness analysis employed 
a cohort, semi-Markov model following men from age 30 to death. A range of PSA 
screening strategies were compared with no PSA testing and an extensive series of 
increases with higher test costs, smaller subgroup and smaller incremental effects 
due to the treatment change. cOnclusiOns: The data collection of costs, survival 
and quality of life of PMAs should be restricted to the subgroup for whom treat-
ment changes. Therefore, cost-effectiveness analyses of PMAs should start with 
identifying that subgroup. Once the size of the subgroup, the cost-effectiveness 
of the treatment change and the test costs are known, the full cost-effectiveness 
can be easily calculated. The described function can also be used to assess the 
potential cost-effectiveness of future PMAs. If a PMA causes a treatment change 
in a small subgroup, the PMA can only be cost-effective with low test costs or 
large incremental effects.
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Objectives: Health economic evaluations (HEEs) of vaccines are commonly con-
sidered during immunization introduction decision-making processes in most 
industrialized countries. Despite the availability of guidelines advocating more 
standardization for such HEEs, there are still several infection/immunization-spe-
cific particularities that are debated in the scientific community. An international 
expert-workshop was convened to identify good practices for (i) how to conduct 
HEEs of vaccines and (ii) how to consider results of HEE in vaccine introduction 
decision-making. MethOds: A systematic literature search was conducted to 
identify prevailing opinions and remaining issues of HEE in vaccination. Twenty-
two experts in the field of health economics and immunization decision-making 
were invited to a workshop and were asked to answer a survey-questionnaire 
based on the systematic literature search beforehand to inform the prepara-
tion of group work sessions (GWS). In GWS, issues focusing on ‘mathematical 
modeling’, ‘health economics’, and ‘decision-making’ were discussed and sum-
marized. Results: The GWS (based on systematic literature search) included 
topics such as cost-components, quality of life (QoL), discounting, and perspec-
tives leading to suggestions such as including caregiver QoL impact and applying 
decreasing time-related discount rates. Since vaccination often causes indirect 
effects, the use of dynamic models is required and exceptions should be justi-
fied. In order to facilitate transparent decision-making, the results of HEE should 
present parameter and methodological uncertainty as well as cumulative and 
time-specific figures. The majority of countries in Europe use results from HEEs 
in an informal judgment-process without willingness to pay (WTP) threshold. The 
expert-group emphasized that transparency should be maximized in decision-
making process. cOnclusiOns: The deliberations led to suggestions on several 
HEE issues. However, vaccines not always need to be considered differently in HEE 
since other interventions might share similar characteristics. Transparency in the 
conduct and presentation of HEE, and subsequent decision-making is essential, 
especially in the absence of explicit WTP thresholds.
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Objectives: To apply in practise an MCDA framework for the value assessment of 
a set of therapeutic options in regards to an oncology indication through an HTA 
simulation exercise. MethOds: Using MCDA principles, past research outcomes 
and the clinical and economic literature, a disease specific value tree was con-
structed incorporating the values concerned as criteria. The alternative options 
were scored against the criteria through the development of value functions, 
weights were assigned to the criteria using a swing method, scores and weights 
were aggregated using a linear additive model, and sensitivity analysis of the results 
was conducted. All the stages were informed by extensive stakeholder engage-
ment through their participation at a decision conference workshop. Results: 
Value parameters considered included burden of illness, therapeutic, safety, inno-
vation and socioeconomic criteria. Overall value scores were produced reflecting 
the performance of the options against the criteria while considering their relative 
importance. Hypothetical payer’s resource allocation decisions on the coverage of 
the options were made on “value for money” grounds through the use of “cost-per-
unit of value” that was derived by incorporating purchasing costs. cOnclusiOns: 
MCDA possesses the prerequisites of a value based assessment methodological 
framework. The multiplicity of criteria that can be incorporated to assess value, 
the weights that can be applied to the criteria, and the stakeholders’ involvement 
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clarifying and updating ClinRO information. MethOds: PROQOLID was searched on 
April 9, 2014 to retrieve current information about ClinROs using an advanced search 
engine. Results: The ClinRO information was found under the category “mode of 
administration” in the subcategory “clinician-rated.” Out of the 801 questionnaires 
in the database, fifty-two (6.5%) were identified as ClinROs. Out of these 52 ques-
tionnaires, nine were generic. Eight different therapeutic areas were identified (i.e., 
digestive system diseases, musculoskeletal diseases, neoplasms, nervous system 
diseases, respiratory tract diseases, psychiatric disorders, pathological conditions 
signs and symptoms, and skin and connective tissue diseases), representing 17 dif-
ferent indications, and 33.33% of the therapeutic areas included in PROQOLID (n= 24). 
The most represented therapeutic area was psychiatry (n= 23) followed by nervous 
diseases (n= 7). Only two questionnaires were specific to children: the Pediatric 
Evaluation of Disabilty Inventory and the WeeFIM®. To better individualize ClinRO 
information in PROQOLID, it is proposed to create a new meta-category, i.e., type of 
COA (PRO, ClinRO, ObsRO and PerfRO). It is also recommended to expand PROQOLID 
to all COAs. cOnclusiOns: This review has shown that PROQOLID already includes 
ClinRO information. Recommendations are given on how to modify the organization 
and content of the database to present information on all COAs.
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Objectives: Electronic Clinical Outcome Assessments (eCOAs) are increasingly 
being used in clinical trials and their use is encouraged by regulatory authorities. 
Licensing is a key issue for their appropriate utilization. The objective of this abstract 
is to make recommendations about eCOA licensing using lessons learned from the 
COA translation licensing. MethOds: Publications about licensing of COA transla-
tions were searched and a review of the eCOAs specificities was performed using 
information available from e-vendors. Results: Very few publications exist about 
the licensing of COA translations. The ISOQOL TCA SIG has developed a draft reflec-
tion paper which considers that translations are derivative work of original ques-
tionnaires. As such, they recommend that the copyright of a COA and its translations 
should be owned by a unique entity, generally the original developer to harmonize 
and facilitate conditions of access and use. They state that distribution should be 
centralized to facilitate access to questionnaires, maintain reliable information 
about them, and control their use. Review of the e-vendors information shows that 
eCOAs are often customized, with proprietary devices and softwares, and cannot be 
shared across users. As a consequence, there is a multiplication of e-versions for a 
same content. Equivalence between paper and e-versions and between e-versions 
is then a major concern. The review also shows that migration from paper to the 
electronic platform/device implies changes to the content and format of the paper 
version. Therefore the eCOAs can be considered as derivative works of an original 
COA and lessons learned from copyright of translations may apply. Examples will 
be provided. cOnclusiOns: Centralized copyright ownership by the owner of the 
original COA and centralized licensing process for eCOAs should be discussed with 
all stakeholders to help controlling use and users and to protect the integrity of 
the instrument across e-versions by providing clear rules of e-implementation.
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Objectives: To determine how European databases are used to support pharmaco-
epidemiological research. Randomised, controlled trials remain the gold standard 
for evaluation of drug efficacy and safety. However, the only way of identifying treat-
ment pathways and improving understanding of real world costs and outcomes at 
different stages of care is via longitudinal observational studies. Observational data 
from electronic health records (EHRs) are essential to this pharmaco-epidemiologi-
cal research. Different European databases have different strengths in terms of data 
types and availability. Identifying these strengths will help to select the right data-
base for a particular study. In this context, one approach to increasing our under-
standing is to analyse types of published data to determine how databases have 
historically been used to support research. MethOds: We identified peer-reviewed 
publications over the last 10 years from one popular longitudinal general practice 
patient database with some secondary care links. The publications were assigned 
to disease areas and study types (e.g. prevalence, resource utilisation, treatment 
patterns, outcomes etc). Results: Based on this mapping exercise, we identified 
the types of studies and the disease areas that this European database commonly 
supports. We also highlight gaps in disease area coverage and types of real world 
evidence studies and discuss potential reasons for this underuse. cOnclusiOns: 
European observational data from EHRs provide increasingly important information 
for stakeholders of new treatment, however there are still a number of gaps in terms 
of disease areas and study types that these databases can support.
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Objectives: The lack of accessible, comprehensive sources of medical and quality 
of life data in Germany has partially hindered the ability to research diabetes clinical 
practice. The aim of this study was to build a prospective, national, multi-centre Type 
2 diabetes mellitus (T2DM) registry using an innovative data collection methodol-
ogy to better understand the disease specific epidemiology, treatment patterns and 
scenario analysis was employed. PSA cut-off levels were varied between > 3ng/ml 
and > 4ng/ml reflecting European guidance and practice variation in Ireland. Costs 
and benefits were discounted at 5% per annum. Results: Extensive probabilistic 
sensitivity analyses highlighted wide variation in incremental cost-effectiveness 
ratios (ICERs). PSA testing may be cost effective using a once-off test at age 50 or age 
55 depending on the ceiling ratio incorporated. Results for the ≥ 3ng/ml PSA cut-off 
consistently dominated those for the ≥ 4ng/ml PSA cut-off. cOnclusiOns: This 
analysis illustrates the value MPES methods for economic modelling of interven-
tions. The results contribute to the ongoing accumulation of evidence on the costs 
and benefits of PSA testing internationally.
ReseaRCH on MetHods – databases & Management Methods
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Objectives: Despite advances in chronic lymphocytic leukemia (CLL) treatment, 
roughly 25% of first and 50% of second line patients experience relapse. Relapse, 
however, is not well coded in claims data and is not well documented in EMR data 
due to under reporting of patient status, variability in terminology used to report 
patient status, and change in disease progression over time. The goal of this analysis 
was to develop an algorithm to identify relapsed patients when patient status is 
not clearly documented. MethOds: CLL patients in the MarketScan® Oncology 
EMR Database with recorded patient status were identified. Relapse was explored 
using two methods: 1) recorded patient status of relapse; 2) changes in laboratory 
data. For the first phase of algorithm development, both indications of relapse were 
compared to the date of treatment initiation. Laboratory data included lymphocytes, 
platelets, and hemoglobin. Results: Of 18,334 patients with CLL, 7,865 (43%) had 
any patient status reported. 528 had any mention of either relapse or remission 
and 73 (1%) patients had a record for relapse on the same date as a CLL diagnosis 
and no evidence of any other cancer types. For these 73 patients, the date of new 
treatment initiation had no relationship with the date of the first recorded relapse. 
Among these same patients, declines in hemoglobin and platelets, and increases in 
lymphocytes preceded treatment initiation by several days. cOnclusiOns: Patient 
status does not appear to be updated regularly and documented status may not 
indicate decision to treat. This preliminary work suggests that lab data provide a 
viable source for algorithm development as they are regularly reported in the EMR 
and for CLL are likely linked to decision to treat. Next steps include determining 
the specific rule for identifying the change in lab values that triggers treatment 
initiation or resumption.
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Objectives: Evaluating effectiveness of oncological treatments and their costs 
becomes more and more important with respect to the high burden of malignant 
diseases. The aim of this research was to estimate the occurrence, survival and 
health care cost of colorectal-, breast-, prostate- and lung cancer patients based on 
the National Health Insurance Fund (NHIF) database. MethOds: Survival and cost 
analyses were performed on the NHIF database. Inclusion criteria: at least two con-
secutive ICD codes between 2000 and 2012, with a minimum of 30 days difference; 
or those with one ICD code, followed by death within 60 days. The following ICDs 
were considered: C18-C20 (colorectal), C33-C34 (lung), C50 (breast), C61 (prostate). 
428 860 social security numbers met our inclusion criteria. The following indicators 
were estimated: number of new cases, mortality, time from diagnosis to treatment, 
survival and annual costs related and not related to the disease. Results: In 2011, 
the numbers of new cases were the following: colorectal cancer: 7299 breast cancer: 
5842, prostate cancer: 3162, and lung cancer: 5499. The probability of 5-year over-
all survival from first diagnosis were 41.3%, 75.2%, 62.1% and 17.1%, respectively. 
Median time from first diagnosis to treatment initiation was less than 1 month 
in colorectal-, breast- and prostate cancer and less than 2 months in lung cancer. 
Annual cost of patient was 3166 EUR (colorectal cancer), 2585 EUR (breast cancer), 
2833 EUR (prostate cancer) and 4158 EUR (lung cancer), respectively (2011 average 
exchange rate: 279.21 HUF/EUR). These figures indicate that annual cost of care of 
these malignant patients are less than half of the annual cost of kidney transplanted 
and haemophilia patients estimated with similar methodology. cOnclusiOns: 
Data suggest that payer’s database is suitable for estimating epidemiologic and 
economic indicators of malignant disorders. Payer’s database analysis can support 
evidence-based policy-making.
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Objectives: In 2002, PROQOLID was launched to provide an overview of existing 
PRO instruments. In October 2011, the term Clinical Outcome Assessments (COAs) 
was introduced to better reflect the importance of the source of information in 
measurements: patients (PROs), clinicians (ClinROs), and observers (ObsROs). In May 
2013, a new category was added: Performance outcome assessments (PerfOs). With 
this evolving taxonomy, including information about all COAs might become a cru-
cial step in developing PROQOLID. The objective of this study was: (1) To review how 
ClinROs are currently reported in PROQOLID; and (2) To propose (if needed) ways of 
